2026-06-14T02:28:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/202402024-11-28T17:34:58Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16968col_20.500.12105_16983

00925njm 22002777a 4500 dc Zheng, Yan author Hu, Frank B author Ruiz-Canela, Miguel author Clish, Clary B author Dennis, Courtney author Salas-Salvado, Jordi author Hruby, Adela author Liang, Liming author Toledo, Estefanía author Corella, Dolores author Ros, Emilio author Fito, Montserrat author Gomez-Gracia, Enrique author Aros, Fernando author Lapetra, Jose author Serra-Majem, Lluis author Estruch, Ramon author Martinez-Gonzalez, Miguel A author 2016-09 Background: Glutamate metabolism may play a role in the pathophysiology of cardiometabolic disorders. However, there is limited evidence of an association between glutamate-related metabolites and, moreover, changes in these metabolites, and risk of cardiovascular disease (CVD). Methods and Results: Plasma levels of glutamate and glutamine were measured at baseline and 1-year follow-up in a case-cohort study including 980 participants (mean age 68 years; 46% male) from the PREvencion con DIeta MEDiterranea (PREDIMED) randomized trial, which assessed a Mediterranean diet intervention in the primary prevention of CVD. During median 4.8 years of follow-up, there were 229 incident CVD events (nonfatal stroke, nonfatal myocardial infarction, or CVD death). In fully adjusted models, per 1-SD, baseline glutamate was associated with 43% (95% CI: 16% to 76%) and 81% (39% to 137%) increased risk of composite CVD and stroke alone, respectively, and baseline glutamine-to-glutamate ratio with 25% (6% to 40%) and 44% (25% to 58%) decreased risk of composite CVD and stroke alone, respectively. Associations appeared linear for stroke (both P-linear trend <= 0.005). Among participants with high baseline glutamate, the interventions lowered CVD risk by 37% compared to the control diet; the intervention effects were not significant when baseline glutamate was low (P-interaction=0.02). No significant effect of the intervention on year-1 changes in metabolites was observed, and no effect of changes themselves on CVD risk was apparent. Conclusions: Baseline glutamate was associated with increased CVD risk, particularly stroke, and glutamine-to-glutamate ratio was associated with decreased risk. Participants with high glutamate levels may obtain greater benefits from the Mediterranean diet than those with low levels. Zheng Y, Hu FB, Ruiz-Canela M, Clish CB, Dennis C, Salas-Salvado J, et al. Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvencion con DIeta MEDiterranea (PREDIMED) Trial. J Am Heart Assoc. 2016 Sep;5(9):e003755. 10.1161/JAHA.116.003755 2047-9980 Journal of the American Heart Association http://hdl.handle.net/20.500.13003/17180 27633391 L618953066 2-s2.0-85016728658 http://hdl.handle.net/20.500.12105/20240 386716900037 Cardiovascular disease Diet Dietary clinical trial Epidemiology Glutamate Glutamine Incidence Stroke Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvencion con DIeta MEDiterranea (PREDIMED) Trial